Momordica Charantia Extract Research Articles

Formulation and evaluation of herbal gel containing ethanolic extract of Momordica charantia against socransky’s periodontal pathogens of the oral cavity-an in vitro study

Background: Periodontitis is a multifaceted disease initiated by periodontal pathogens which when left untreated results in inflammation of the supporting tissues of the teeth, resorption of alveolar bone, loss of the periodontal ligament attachment, periodontal pocket formation and/or recession of the gingiva. Hence, the current study aimed at evaluating the efficacy of Momordica charantia leaves extract on Socransky’s periodontal pathogens and formulating a herbal gel for subgingival local drug delivery for the potential treatment of moderate periodontitis. Methods: M. charantia leaves were authenticated from a recognized taxonomist. They were coarsely powdered following which an ethanol-based extract preparation was done. The extract obtained was then assessed for minimum inhibitory concentration, minimum bactericidal concentration followed by gel formulation which was then subjected to time kill assay and zone of inhibition on periodontal pathogens, the efficacy of which was comparatively evaluated against 0.12% chlorhexidine (CHX) gluconate. Kruskal-Wallis Test was employed with the statistical significance set at p≤0.05. Results: The concentration of M. charantia ethanolic extract against periodontal pathogens was determined to be 1 gm/100 ml and a statistically significant difference was found in the effectiveness between the gel so formulated and CHX. Conclusion: The antibacterial activity was evident in the ethanolic extract of M. charantia which when used to formulate a herbal gel against anaerobic periodontal pathogens demonstrated efficacy comparable to that of CHX.

Impact of Bitter Gourd (Momordica charantia) Hypoglycemic Formulation on Biochemical Parameters in Alloxan-induced Diabetic Albino Rats

Introduction: Diabetes mellitus is a widespread endocrine disorder that leads to chronic hyperglycemia, posing significant health challenges globally. Effective management of blood glucose levels remains a critical goal in diabetes treatment. Recent studies have highlighted the potential of natural products in diabetes management. Momordica charantia, commonly known as bitter gourd, has been traditionally used for its purported hypoglycemic effects. This study aims to evaluate the efficacy of a methanolic extract of Momordica charantia in reducing blood glucose levels in an animal model of diabetes and compare its effectiveness to a standard antidiabetic medication, Glizid-M. Materials and Methods: The study utilized alloxan-induced diabetic albino rats to assess the hypoglycemic effects of the methanolic extract of Momordica charantia. Diabetic rats were divided into groups and administered varying doses of the extract: 150 mg/kg, 300 mg/kg, and 600 mg/kg. A control group received Glizid-M, and a baseline group received no treatment. Blood glucose levels were monitored at regular intervals to evaluate the efficacy of the extract in managing hyperglycemia. Results and Discussion: The administration of the methanolic extract of Momordica charantia resulted in a dose-dependent reduction in blood glucose levels. Among the tested dosages, the 600 mg/kg dose demonstrated a statistically significant decrease in blood glucose compared to the lower doses of 150 mg/kg and 300 mg/kg. The 600 mg/kg dosage showed comparable efficacy to the standard antidiabetic drug, Glizid-M, indicating a strong hypoglycemic effect. The results of this study suggest that Momordica charantia has a potent hypoglycemic effect, with its efficacy increasing with dosage. The significant reduction in blood glucose levels at the highest dosage implies that the extract may influence glucose metabolism effectively. The dose-dependent response highlights the importance of optimizing dosage for maximum therapeutic benefit. Comparison with Glizid-M further supports the potential of Momordica charantia as a viable alternative or complementary therapy in diabetes management. Conclusion: This study provides scientific validation for the use of Momordica charantia methanolic extract as a therapeutic agent for diabetes management. The observed dose-dependent reduction in blood glucose levels suggests its potential as an effective natural remedy for controlling hyperglycemia. Further research is warranted to explore the underlying mechanisms and long-term efficacy of this extract in diabetes treatment.

Pharmacokinetic and Pharmacodynamic Interactions of Momordica charantia extract with Glibenclamide in Streptozotocin induced Diabetic rats

Diabetes mellitus (DM) has emerged as a leading global health problem. Diabetes is estimated to affect 425 million adults globally. Majority of diabetic patients take herbal medicines as supplement for the treatment of diabetes. The combined use of herbs and modern synthetic medicine has increased the possibility of pharmacokinetic (PK) and pharmacodynamic (PD) interactions. Momordica charantia (MC) commonly known as bitter melon/bitter gourd, is globally marketed for treatment of diabetes. Many diabetic patients consume MC extract along with antidiabetic drugs for better therapeutic effect with or without knowledge of health care provider.The current study evaluated PKPD herb-interaction of MC extract with glibenclamide (GLB) following oral administration either alone or in combination with MC extract for 28-consequative days. MC extract co-administratioin showed increased plasma exposure of GLB on Day-28 compared to glibenclamide alone treated groups with similar dosing regimen. Glibenclamide upon co-administration with MC extract showed improved pharmacodynamic parameters compared to glibenclamide alone treated groups suggesting synergistic or additive effect. Physician can reduce the glibenclamide dose in diabetic patients if they are taking MC as supplement.

Anti-diabetic, Anti-cancer Potential and Anti HIV of Bitter Gourd (Momordica charantia) Extract: A Mini Review

Aims: To review the antidiabetic properties, pharmacological characteristics, and phytochemical research on Momordica Ccharantia (bitter gourd) and assess its potential as a therapeutic agent for diabetes and cancer prevention. Study Design: Review of existing literature and research studies, including pre-clinical trials and animal and in vitro studies. Methodology: Analysis of traditional uses, pharmacological data, and phytochemical research on M. Charantia. Evaluation of anti-diabetic and anti-HIV properties based on available studies. Results: Charantia has shown anti-diabetic and hypoglycemic effects in pre-clinical studies. Limited and unreliable clinical data due to poor research design and inadequate statistical power. Recent studies indicate potential anti-tumor, anti-diabetic, and anti-HIV properties. Plant extract components have demonstrated effectiveness in cancer prevention through immune function enhancement, induction of cell death, and inhibition of cancer-related processes. Conclusion: M. Charantia holds promise as a therapeutic agent for diabetes management and cancer prevention. However, there is a need for better-designed clinical trials to confirm its efficacy and establish reliable clinical evidence.

Phytochemical Screening and Evaluation of Anti Diabetic Activity Using Momordica charantia (Leaf & Stem) Extracts in Alloxan Induced Rats

Purpose: Current procedure is to find out the effect of anti-diabetic using Momordica Charantia (leaf and stem) extracts on Alloxan induced experimental rats. Methods: The leaf and stem extracts of Momordica charantia were prepared by using cold maceration technique. The obtained filtrates are then subjected to a distillation process to obtain pure and concentrated products. The phytochemical studies were performed for both the extracts. Wet granulation method was done for preparation of tablets. The α-Amylase inhibition assay was done to both leaf and stem extracts as an in vitro method and Alloxan induced anti diabetic method was done as an in vivo process for the experimental animals. At last creatinine and urea levels were estimated. Results: The phytochemical results of both leaf and the stem extracts were shown positive for phenols, tannins, flavonoids, glycosides, steroids, oils, fats and for alkaloids. The weight of the granules were reduced and found to be F1- 15.32gm, for granules F2-14.37gm, for granules F3-14.39gm and for granules F4- it was 13.83gm. For α-amylase inhibition assay the standard acarbose 58.70% of inhibition for 100 μg/ml concentrations, the leaf extract showed 80.58% of inhibition for 100μg/ml concentration and the stem extract showed 86.45% of inhibition for 100μg/ml concentration. In fasted rats for the extract-1 (leaf) the highest blood glucose level was seen at 0 min as 82(mg/dl) and for the extract-2(stem) the highest blood glucose level was seen at 0 min as 84(mg/dl). And for the Oral glucose tolerance test the extract-1(leaf) the highest blood glucose level was seen at 120 min as 119(mg/dl) and for the extract-2(stem) the highest blood glucose level was seen at 120 min as 108(mg/dl). Conclusion: The study attests to the therapeutic effects of the chosen plant extracts, which have been demonstrated to help prevent and regulate blood glucose levels. Furthermore, in managing diabetes and its associated problems. Momordica charantia plant extracts from the leaves and stems have demonstrated anti-hyperglycemic properties. The results of this investigation indicated that there was a notable antidiabetic response to the treatment using plant extracts (leaf < stem).

Anti-Infective Activity of Momordica charantia Extract with Molecular Docking of Its Triterpenoid Glycosides.

Momordica charantia, commonly known as bitter melon, is a fruiting plant that has been used for several diseases including infectious diseases. In this study, we report the antibacterial, antifungal, and antiviral activity of different bitter melon fruit parts originating from India and Saudi Arabia. The in vitro experiments are supported by the molecular docking of karavilosides to verify their role in the bioactivity. The antimicrobial assays revealed activity against Candida albicans, Escherichia coli, and Staphylococcus aureus. The extracts exhibited the potent inhibition of HIV-I reverse transcriptase, with an IC50 of 0.125 mg/mL observed for the pith extract originating from Saudi Arabia and the standard drug doxorubicin. The molecular docking of karavilosides exhibited a significant affinity to reverse transcriptase comparable to Rilpivirine and higher than that of doxorubicin. These outcomes encourage the precious bioactive components of the seed and pith of the Saudi bitter melon fruits to be further studied for isolation and structure elucidation.

Momordica charantia Leaf Extract Mediated Zinc Oxide Nanoparticles for Antibacterial Performance

We uncovered a simple and conservational process for the production of zinc oxide nanoparticles (ZnO NPs). This was accomplished by a biosynthetic method that included the leaf extract of Momordica charantia as a reducing agent. The UV-Vis absorption spectrum of them exhibits maxima at 352 nm. The presence of bands at 630cm-1 in the Fourier transform infrared spectrum verifies the production of zinc oxide nanoparticles. XRD determined that the particle size ranged between 20 and 58nm. Field emission scanning electron microscopy exposed that the ZnO NPs were irregular in nature and ranged in size from 20 to 60nm. The existence of oxygen and zinc in ZnO NPs is verified by energy-dispersive X-ray analysis. ZnO NPs exhibited strong antibacterial action against Klebsiella pneumoniae and Staphylococcus aureus. This biosynthetic technique could pave the way for simple, cost-effective, environmentally friendly products that avoid toxic chemicals and are helpful for applications in medication and the large-scale manufacture of nanoparticles.

Momordica charantia Bioactive Components: Hypoglycemic and Hypolipidemic Benefits Through Gut Health Modulation.

Momordica charantia (MC), a member of the Cucurbitaceae family, is well known for its pharmacological activities that exhibit hypoglycemic and hypolipidemic properties. These properties are largely because of its abundant bioactive compounds and phytochemicals. Over the years, numerous studies have confirmed the regulatory effects of MC extract on glycolipid metabolism. However, there is a lack of comprehensive reviews on newly discovered MC-related components, such as insulin receptor-binding protein-19, adMc1, and MC protein-30 and triterpenoids 3β,7β,25-trihydroxycucurbita-5,23(E)-dien-19-al, and the role of MC in gut microbiota and bitter taste receptors. This review offers an up-to-date overview of the recently reported chemical compositions of MC, including polysaccharides, saponins, polyphenolics, peptides, and their beneficial effects. It also provides the latest updates on the role of MC in the regulation of gut microbiota and bitter taste receptor signaling pathways. As a result, this review will serve as a theoretical basis for potential applications in the creation or modification of MC-based nutrient supplements.

Effect of probiotics, antibiotics and herbal extracts against fish bacterial pathogens

In this study the effect of probiotic preparations and plant extract was investigated against eleven fish bacterial pathogens viz. Aeromonas hydrophila, Cellobiococcus sp., Enterobacter aerogenes, E. cloacae, Klebsiella pneumoniae, Salmonella sp., Shigella sp., Streptobacillus sp., Streptococcus sp., Pseudomonas fluorescens and Staphylococcus aureus. All these pathogens were found to be resistant for antibiotics viz. nitrofurantoin, amoxycillin, bacitracin, cephalothin, erythromycin, novobiocin, vancomycin , amphicillin, oxacillin and colistin. In vitro antagonism test of the probiotics was performed by using well diffusion method. In case of probiotic AquaproTM, effective zone of inhibition of 2.433 cm was observed for P. fluorescens and K. pneumoniae. The extracts of Azadirachta indica, Aloe barbadensis, Withania somnifera and Momordica charantia were studied in vitro alone as well as in combination with probiotic (Lactobacillus sporogenes). The zone of inhibition observed in mixed sample was less as compared to individual sample. Among the four plants extract, the W. somnifera extract was found to be the most effective and it leads to maximum inhibition (1.1 cm) recorded for E. aerogenes.

Comparative Study on Anti-Diabetic Activity of Momordica charantia and Psidium guajava

Diabetes is a metabolic disease characterised by decreased insulin signalling and persistent hyperglycaemia. The most frequent progression of diabetes is known as diabetes mellitus which is defined as persistent hyperglycaemia brought on by either peripheral insulin resistance or impaired pancreatic β cell production of insulin. This condition is caused by the disruptions in the digestion of carbohydrates, fats and proteins which are caused by defects in the production, release and regulation of insulin. The breakdown of carbohydrates is significantly aided by the intestinal digestive enzymes α-glucosidase and α-amylase. One type of antidiabetic treatment is to lower the blood glucose levels after a meal by blocking the enzymes α-glucosidase and α-amylase. This could be a key tactic in blood glucose control. When compared to other commercial pharmaceuticals used to treat diabetes, herbal treatments are thought to be more in harmony with the human body and to have less harmful side effects. This herbal remedy is reasonably priced as well. The aim of the current study is to compare the anti- diabetic activity of the methanolic extracts of Momordica charantia and Psidium guajava. The methods used in the determination of invitro antidiabetic activity are alpha amylase and alpha glucosidase inhibitory assays. In the current study, when compared the individual inhibition activity of Momordica charantia and Psidium guajava on the intestinal enzymes (alpha amylase and alpha glucosidase), Momordica charantia has the highest inhibition that is 79.83% at 0.8 mL concentration while the Psidium guajava has shown only 70.58% inhibition at 0.8 mL concentration. Which suggests that the presence of bio active compounds may be responsible for the plants many medicinal uses, including the treatment of diabetes.

In-vitro Evaluation of Wild Bitter Melon (Momordica charantia) Extracts against Periodontopathic Bacteria (Prevotella intermedia and Porphyromonas gingivalis) using Antibacterial, Anti-Inflammatory and Molecular Docking Analysis.

Wild bitter melon (Momordica charantia) extracts were prepared and their antibacterial and anti-biofilm assay were investigated against two different periodontopathic bacteria (Prevotella intermedia and Porphyromonas gingivalis) for the first time to the best of our knowledge based on the presence of different phytochemical compounds. Momordica charantia solvent extracts were prepared and phytochemical analysis was performed. Minimal inhibitory and bactericidal concentrations were determined. Antibacterial activity was evaluated using the standard well diffusion method. Anti-inflammatory studies on periodontal ligament (PDL) cell viability and lipopolysaccharide (LPS)-induced inflammation were performed. Molecular docking was investigated between the bioactive compound (Charantadiol A) of plant extract and biofilm-expressing genes in each test organism. Phytochemicals from ethanol extract showed promising results; alkaloids, flavonoids, phenols, and tannins were found present at considerable levels. The minimum inhibitory concentration was found to be 400 μg/mL for Prevotella intermedia and Porphyromonas gingivalis. Antibacterial activity expressed in terms of zone of inhibition showed 14 mm to 18 mm zones against the test organisms. The molecular docking report revealed the maximum binding energy of about -6.54 Kcal/Mol of binding energy between Charantadiol A and fimA of Porphyromonas gingivalis. Anti-biofilm study showed that the minimum biofilm eradication concentration (MBEC) of Momordica charantia expressed significantly good results against the test organisms. The PDL cell viability values expressed in percentage indicated the anti-inflammatory properties of Momordica charantia extracts at three different known concentrations. The findings concluded that Momordica charantia extracts have promising prospects as an anti-periodontopathic and anti-inflammatory agent.

Ameliorative effects of aqueous extract of Momordica charantia seed against Collagen induced Rheumatoid Arthritis in rats

Ameliorative effects of aqueous extract of Momordica charantia seed against Collagen induced Rheumatoid Arthritis in rats

Evaluation of antioxidant and antacid activities of crude methanol and peptide extracts of Momordica charantia, Luffa cylindrica, and Jatropha curcas

Background: There are many uses for therapeutic-based compounds in the food and pharmaceutical industries, and natural products are one of the best sources of these compounds. Momordica charantia (Family Cucurbitaceae), Luffa cylindrica (Family Cucurbitaceae), and Jatropha curcas (Family Euphorbiacece) have been documented for various medicinal applications. Objective: This study aimed to assess the anti-ulcer and antioxidant properties of M. charantia, L. cylindrica and J. curcas extracts and their crude peptide. Methods: The plant samples were collected, identified, and authenticated at Forest Herbarium, Ibadan, Nigeria. The samples were allowed to air dry, were pulverized, and then were extracted using methanol. The peptidic principles were extracted using Dichloromethane: Chloroform: Water mixtures in the ratio 1:1:0.5 and concentrated in vacuo. The peptidic extracts were screened for peptide and peptide-related compounds by TLC bioautography using Ninhydrin, Pyridine, and modified G-250 reagents. The extracts were assessed for antioxidant (2,2-diphenyl-1-picrylhydrazyl, DPPH), free radical scavenging activity, total phenolic content (TPC), total flavonoid content (TFC), and antiulcer activity. The antiulcer activity was evaluated using the artificial gastric acid neutralizing activity. Results: It was observed that all M. charantia, L. cylindrica, and J. curcas and their crude peptide extracts contain phenols and flavonoids. The TPC values of the crude methanol extracts were greater than those of the corresponding peptide extracts for all three species. The TFC of M. charantia and L. cylindrica crude methanol extracts were lower than their crude peptide extracts, while the TFC of J. curcas crude methanol extract was higher than the TFC value for its crude peptide extract. The DPPH radical scavenging activity of the crude extracts and crude peptide extract of M. charantia, L. cylindrica, and J. curcas was low when compared to the standard (Gallic acid). The M. charantia crude peptide extract had the lowest IC50 value of 282.4 μg/mL, indicating that it had better scavenging efficacy compared to the other extracts that were examined, while the lowest IC50 value was obtained from J. curcas methanol extracts (411.7 μg/mL). The result from this study shows that M. charantia, L. cylindrica, and J. curcas and their crude peptide possess artificial gastric acid neutralizing activity, which implies that they can be used as antacids to reduce the acidity of the stomach. Hence, the plants were evaluated for their efficacy in managing peptic ulcers by their ability to reduce the acidity of the stomach by raising the pH of the stomach. This is the first report on the antacid potential of Momordica charantia, Luffa cylindrica, and Jatropha curcas in literature. Conclusions: The results from this study support the ethnomedicinal claims that M. charantia, L. cylindrica, and J. curcas can be used in the management of peptic ulcers, and these plants could serve as sources of lead compounds to produce natural antiulcer drugs. There were traces of the presence of linear peptides and cyclic peptides (cysteine-rich cyclotides). Keywords: Antiulcer, Antioxidant, Peptides, Momordica charantia, Luffa cylindrica, Jatropha curcas

Green fabrication of silver nanoparticles using leaf extract of tropical vine Momordica charantia: spectral characterization and in vitro cytotoxicity evaluation on human breast cancer cells

ABSTRACT The use of environmental materials such as plant extract for the synthesis of silver nanoparticles (AgNPs) offers numerous benefits of eco-friendliness and compatibility for pharmaceutical and other biomedical Applications. In this study, we used Momordica charantia leaf extract as a reducing agent for the synthesis of AgNPs. Characterization of the AgNPs was done by UV-Visible Spectroscopy, FTIR, SEM, TEM and EDX. Furthermore, we established the in vitro anticancer efficacy of these nanoparticles against the human breast cancer cell line MCF-7 using MTT assay, nuclear morphology testing, and staining. In addition to the above, the anti-bacterial effect was also tested against a range of bacterial isolates using well-diffusion method. These AgNPs also demonstrated impressive results when tested for their free-radical scavenging efficiency on the MCF-7 breast cancer cell line, indicating future potential for their use in medicine. These findings indicated the possible applicability of biosynthesized AgNPs derived from Momordica charantia L.

Potential Anti-Diabetic Benefits of Momordica charantia Extracts on Experimental Diabetes and its Complications

Potential Anti-Diabetic Benefits of Momordica charantia Extracts on Experimental Diabetes and its Complications

Assessment of the crude ethanol leaf extracts of Momordica charantia Linn., Moringa oleifera Lam., Tabernaemontana pandacaqui Poir. and Mollugo oppositifolia Linn. for its wound healing activity in castrated piglets

Assessment of the crude ethanol leaf extracts of Momordica charantia Linn., Moringa oleifera Lam., Tabernaemontana pandacaqui Poir. and Mollugo oppositifolia Linn. for its wound healing activity in castrated piglets

A comparative study: Probiotics number in fermented bitter melon (Momordica charantia) juice decreased blood sugar and lipid profiles

ABSTRACT Purposes - Momordica charantia (MC) contains triterpenes, proteins, and steroids with anti-diabetic and antioxidative properties. Developing type 2 diabetes (T2DM) in prediabetes can be reduced by probiotics consumption. The pathogenesis and progression of diabetes are induced by oxidative stress and followed by elevated triglyceride and cholesterol levels. This study aimed to evaluate blood sugar levels and lipid profiles before and after treatment. Experimental procedure - A total of 24 male Sprague-Dawley rats were induced by a single dose (60 mg/kg) of streptozotocin (STZ) and 120 mg/kg of nicotinamide. Following three days of induction, the rats were randomly divided into four groups and administered 10 ml/kg BW extract for 28 days. DM-MC was treated with MC extract. DM-FMC1 and DM-FMC2 were treated with fermented MC containing 3.7x107 CFU/ml and 3.7x1014 CFU/ml probiotics, respectively. DM-Ctrl was given distilled water. Blood glucose and lipid profile measurements were taken before and after treatment. The data was analyzed using a paired t-test, ANOVA and Tukey HSD for post hoc analysis. The level of significance was set at 0.05. Findings – The groups treated with FMC2 significantly showed a decreased blood sugar level compared to MC and FMC1 (p<0.001), 89.4+3.94, 164.3+2.26, and 109.1+2.07, respectively. Lipid profiles showed the same pattern (p<0.001). Fermented MC substantially decreases blood glucose and lipid profile compared to the MC group (p<0.001). Originality/value - In type 2 diabetes, reducing blood sugar levels and improving lipid profiles are significantly impacted by the presence and number of probiotics.

Insulin secretory actions of polyphenols of Momordica charantia regulate glucose homeostasis in alloxan-induced type 2 diabetic rats

Abstract Objective Momordica charantia, commonly known as bitter gourd, is traditionally used as remedies for various diseases including diabetes. The main objective of this study is to investigate the in vitro and in vivo insulinotropic and antidiabetic effects of an 80% ethanolic extract of M. charantia (EEMC) fruit, as well as the underlying molecular mechanism involved and preliminary phytochemical screening. Methods The insulin secretion was measured using clonal pancreatic BRIN-BD11 β-cells and isolated mouse islets. The ability of EEMC to inhibit carbohydrate digestive enzymes and glucose absorption and to scavenge free radicals was assessed via starch digestion, glucose diffusion, and 2,2-diphenyl-1-picrylhydrazyl assay methods. The effects of EEMC on a variety of metabolic parameters were evaluated in alloxan-induced type 2 diabetic rats, including lipid profile. Finally, a preliminary phytochemical screening was conducted to identify the active phytoconstituents. Key findings EEMC increased insulin release through the KATP-dependent/cyclic adenosine monophosphate pathway, which depolarizes the β-cell membrane and elevates intracellular calcium. It also inhibited glucose absorption and free radicals, suggesting its potential to delay gastric emptying, attenuate oxidative stress, and reduce inflammatory cytokines. In vivo studies showed that EEMC improves oral glucose tolerance, food intake, fasting blood glucose, plasma insulin, and lipids and promotes intestinal motility. The active phytoconstituents in EEMC, such as flavonoids, alkaloids, tannins, saponins, steroids, and glycosides, are likely responsible for these effects. Conclusion The antihyperglycemic properties of EEMC indicate that it might be a promising candidate for diabetes management. However, additional study into the application of M. charantia in type 2 diabetes is essential.

Anticoagulant Evaluation of Momordica charantia Fruit Flesh Extract on Prothrombin Time and Activated Partial Prothrombin Time Test

Thrombotic diseases such as strokes, deep vein thrombosis (DVT), pulmonary embolism are serious consequences of the thrombus formed in blood vessels. The coagulation cascade is a complicated system that involves clotting factor of extrinsic, intrinsic, and common pathways. Imbalance between the process can cause excessive clotting that led to thrombosis. Although several anticoagulants drugs have been developed over the decades, most are accompanied by undesirable side effects such as mild or severe bleeding. Therefore, this study has made use of the natural resources in the search for complementary and alternative therapies. The methanolic extract of Momordica charantia (MC) (bitter gourd) fruit flesh is utilized to identify their effects through in vitro anticoagulant and thrombolytic activity. The anticoagulant activity is tested using prothrombin time (PT) and activated partial prothrombin time (APTT) test with 10, 20 and 30 mg/ml of MC extraction, while the thrombolytic activity is carried out by using clot lysis assay. Momordica charantia fruit flesh methanolic extract was proven to have significant anticoagulant properties at concentration 20 and 30 mg/ml compared to normal and negative control. The extract however was not significant at 10 mg/ml but still demonstrated some anticoagulation effect. It also revealed a substantial thrombolytic activity at 100 mg/ml, when compared to negative and positive control indicating ability to lyse blood clot. It was discovered by our analysis that Momordica charantia fruit flesh possesses significant anticoagulant and thrombolytic activity which can be further exploited in the treatment of blood coagulation disorder.

Emerging Potential of Momordica’s Bioactive Phytochemicals in Cancer Prevention and Therapy

Worldwide, cancer incidence and mortality are rising quickly. Cancer remains the biggest cause of death despite advances in therapy. Plants produce bioactive phytochemicals, and as a result, the bioactive elements have long been the focus of cancer research, both for medication discovery and for the discovery of alternative chemo-preventive methods. The medicinal plant Momordica charantia or bitter melon contains a wide variety of phytochemicals, such as triterpenoids, triterpene glycosides, phenolic acids, flavonoids, lectins, sterols, and proteins. In many pre-clinical systems, the Momordica charantia extract exhibits an anti-cancer action against various malignancies. The bioactive components of the extract play a significant role in its anti-cancer properties. With an emphasis on underlying molecular pathways, we address the roles of Momordica's known bioactive components in several cancer models in this review. Through the inhibition of cancer cell proliferation and induction of cell death, several of active ingredients exhibit cancer prevention and therapeutic effects, at least in in-vitro models. Mechanistically examining the active components in pre-clinical systems may reveal a novel approach to cancer treatment.